Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 4, 2012, Pages 459-473

  Zhanel, George G ^a,b   Lawson, Christopher D ^c   Zelenitsky, Sheryl ^c   Findlay, Brandon ^c   Schweizer, Frank ^a,c   Adam, Heather ^a,b   Walkty, Andrew ^a,b   Rubinstein, Ethan ^a,b   Gin, Alfred S ^a,b,c   Hoban, Daryl J ^a,b   Lynch, Joseph P ^d   Karlowsky, James A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACHN 4 90; aminog lycoside; antibiotic; plazomicin

Indexed keywords

AMIKACIN; CEFEPIME; CEFTOBIPROLE; DAPTOMYCIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PLAZOMICIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERICIDAL ACTIVITY; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FRANCISELLA TULARENSIS; GLOMERULUS FILTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MORGANELLA MORGANII; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PHARMACOKINETICS; PLAGUE; PROTEUS; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA; SINGLE DRUG DOSE; STAPHYLOCOCCUS SAPROPHYTICUS; TULAREMIA; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; YERSINIA PESTIS;

AMIKACIN; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; GENTAMICINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SISOMICIN; TOBRAMYCIN;

EID: 84860121256     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.25     Document Type: Review

References (78)

1. Dozzo P, Moser HE. New aminoglycos ide antibiotics. Expert Opin. Ther. Pat. 20(10), 1321-1341 (2010).
2. Gilbert DN. Aminoglycosides. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell GL, Douglas RG, Bennett JE, Dolin R (Eds). Elsev ier/Churchill L ivingstone, NY, USA, 328-356 (2005).
3. Mathews A, Bailie GR. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and am inoglycoside dosing services. J. Clin. Pharm. Ther. 12(5), 273-291 (1987). (Pubitemid 18081022)
4. Avent M, Rogers B, Cheng A, Paterson D. Current use of aminoglycosides; indic ations, pharmacokinetics and monitoring for toxicity. Intern. Med. J. 41(6), 441-449 (2011).
5. Craig WA. Optimizing aminoglycoside use. Crit. Care Clin. 27(1), 107-121 (2011).
6. Hawkey PM, Jones AM. The changing epidemiology of resistance. J. Antimicr ob. Chemother. 64(Suppl. 1), i3-i10 (2009).
7. Infectious Diseases Society of America. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50(8), 1081-1083 (2010).
8. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57(1), 138-163 (1993). (Pubitemid 23078440)
9. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5(2), 115-119 (2005). (Pubitemid 40174782)
10. Butler MS, Cooper MA. Antibio tics in the clinical pi peline in 2011. J. Antibiot. (Tokyo) 64(6), 413-425 (2011).
11. Aggen JB, Armstrong E S, Goldblum AA et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54(11), 4636-4642 (2010).
12. Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr. Opin. Microbiol. 13(5), 565-573 (2010).
13. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl. Micro biol. Biotechnol. 70(2), 140-150 (2006).
14. Shakil S, Khan R, Zarrilli R, Khan AU. Am inogl ycosides versus bacteria-a description of the action, res istance mechanism, and nosocomial battleground. J. Biomed. Sci. 15(1), 5-14 (2008).
15. Weinstein MJ, Marquez JA, Testa RT, Wagman GH, Oden EM, Waitz JA. Antibiotic 6640, a new Micromonosp ora-produced aminoglycoside antibiotic. J. Antibiot. (Tokyo) 23(11), 551-554 (1970).
16. Bryan LE, Kwan S. Roles of ribosomal binding, membrane potential, and electron tr ansport in bacterial uptake of streptomycin and gentamicin. Antimicrob. Agents Chemother. 23(6), 835-845 (1983). (Pubitemid 13104018)
17. Taber HW, Mueller JP, Miller PF, Arrow AS. Bacterial uptake of aminoglycos ide antibiotics. Microbiol. Rev. 51(4), 439-457 (1987). (Pubitemid 18019282)
18. Hancock RE. Alterations in outer membrane permeability. Annu. Rev. Microbiol. 38, 237-264 (1984).
19. Martin NL, Beveridge T J. Gentamicin interaction with Pseudomonas aeruginosa cell envelo pe. Antimicrob. Agents Chemother. 29(6), 1079-1087 (1986). (Pubitemid 16084073)
20. Davis BD. Mechanism of bactericidal action of a minoglycosides. Microbiol. Rev. 51(3), 341-350 (1987).
21. Hancock RE, Bellido F. Antibiotic uptake: unusual results for unusual molecules. J. Antimicr ob. Chemother. 29(3), 235-239 (1992).
22. Walter F, Vicens Q, Westhof E. Aminoglycoside-RNA interactions. Curr. Opin. Chem. Biol. 3(6), 694-704 (1999).
23. Woodcock J, Moazed D, Cannon M, Davies J, Noller HF. Interaction of antibiotics with A-and P-site-specific bases in 16S ribosom al RNA. EMBO J. 10(10), 3099-3103 (1991). (Pubitemid 21905331)
24. Davies J, Gorini L, Davis BD. Misreading of RNA codewor ds induced by aminoglycos ide antibiotics. Mol. Pharmacol. 1(1), 93-106 (1965).
25. Edelmann P, Gallant J. Mistranslation in E. coli. Cell 10(1), 131-137 (1977). (Pubitemid 8046483)
26. Recht MI, Douthwaite S, Puglisi JD. Basis for prokaryotic specificity of action of aminoglycoside antibiotics. EMBO J. 18(11), 3133-3138 (1999). (Pubitemid 29255621)
27. Lynch SR, Puglisi JD. Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J. Mol. Biol. 306(5), 1037-1058 (2001). (Pubitemid 33030004)
28. Shakya T, Wright GD. Mechanisms of aminoglycoside antibiotic resistance. In: Aminoglycoside Antibiotics. Arya, DP (Ed.). John Wiley & Sons, Inc., Hobok en, NJ, USA, 119-140 (2007).
29. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5), 634-640 (2002). (Pubitemid 34165326)
30. De Stasio EA, Moazed D, Noller HF, Dahlberg AE. Mutations in 16S ribosom al RNA disrupt antibiotic-RNA interac tions. EMBO J. 8(4), 1213-1216 (1989). (Pubitemid 19273288)
31. Prammananan T, Sander P, Brown BA et al. A single 16S ribosom al RNA substit ution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177(6), 1573-1581 (1998). (Pubitemid 28243581)
32. Sander P, Meier A, Bottger EC. Ribosom al drug resistance in mycobacteria. Res. Microbiol. 147(1-2), 59-67 (1996).
33. Savic M, Lovric J, Tomic TI, Vasiljevic B, Conn GL. Determination of the target nucleosides for members of two families of 16S rRNA methyltransferases that confer resistance to partially overlapping groups of aminoglycos ide antibiotics. Nucleic Aci ds Res. 37(16), 5420-5431 (2009).
34. Galimand M, Sabtcheva S, Courvalin P, Lambert T. Worldwide disseminated armA aminog lycoside resistance methylase gene is borne by composite transposon Tn1548. Antimicrob. Agents Chemother. 49(7), 2949-2953 (2005). (Pubitemid 40917615)
35. Wu Q, Zhang Y, Han L, Sun J, Ni Y. Plasm id-mediated 16S rRNA methylases in aminoglycoside-resistant Enterobacte riaceae isolates in Shanghai, China. Antimicrob. Agents Chemother. 53(1), 271-272 (2009).
36. Kojic M, Topisirovic L, Vasiljevic B. Cloning and characterization of an aminoglycoside resistance determinant from Micromonospora zionensis. J. Bacteriol. 174(23), 7868-7872 (1992).
37. Skeggs PA, Holmes DJ, Cundliffe E. Cloning of aminoglycoside-resistance determinants from Streptomyce s tenebrarius and comparison with related genes from other actinomycetes. J. Gen. Microbiol. 133(4), 915-923 (1987). (Pubitemid 17062682)
38. Wachino J, Shibayama K, Kurokawa H et al. Novel plasm id-mediated 16S rRNA m1A1408 methyl transferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob. Agents Chemother. 51(12), 4401-4409 (2007). (Pubitemid 350209896)
39. Yokoyama K, Doi Y, Yamane K et al. Ac quisition of 16S rRNA me thyl ase gene in Pseudomonas aeruginosa. Lancet 362 (9399), 1888-1893 (2003). (Pubitemid 37518504)
40. Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y Global spread of multiple aminoglycoside resistance genes. Emerg Infect. Dis. 11(6), 951-953 (2005). (Pubitemid 40720861)
41. De Stasio EA, Dahlberg AE. Effects of mutagenesis of a conserved base-paired site near the decoding region of Escherichia coli 16 Sribosomal RNA. J. Mol. Biol. 212(1), 127-133 (1990).
42. Alangaden GJ, Kreiswirth BN, Aouad A et al. Me chanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42(5), 1295-1297 (1998). (Pubitemid 28227943)
43. Bryan LE, Kowand SK, Van Den Elzen HM. Mechanism of aminoglycoside antibiotic resistance in anaerobic bacteria: Clostridium perfringens and Bacteroides fragilis. Antimicrob. Agents Chemother. 15(1), 7-13 (1979). (Pubitemid 9099624)
44. Poole K. Efflux-mediated antimicrobial resistance. J. Antimicr ob. Chemother. 56(1), 20-51 (2005). (Pubitemid 41418335)
45. Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Micro biol. Infect. 10(1), 12-26 (2004). (Pubitemid 38128588)
46. Sobel ML, McKay G A, Poole K. Contribution of the MexXY multi drug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical is olates. Antimicrob. Agents Chemother. 47(10), 3202-3207 (2003). (Pubitemid 37229579)
47. Georgescu C, Martin D-A, Bratu S, Quale J, Landman D. Activity of ACHN-490, a novel neoglycosid e antibiotic, against contemporary Gram-negative clinical is olates fr om Brooklyn, N Y hospitals. Presented at: 49th Interscience Conference on Antimicrobi al Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
48. Ramirez MS, Tolmasky ME. Aminoglycos ide modifying enzymes. Drug Resist. Updat. 13(6), 151-171 (2010).
49. Yamada T, Tipper D, Davies J. Enzymatic inactivation of streptomycin by R factor-resistant Escherichia coli. Nature 219(5151), 288-291 (1968).
50. Novick RP, Clowes RC, Cohen SN, Curtiss R 3rd, Datta N, Falkow S. Uniform nomenclature for bacterial plasmids: a proposal. Bacteriol. Rev. 40(1), 168-189 (1976).
51. Foster TJ. Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria. Microbiol. Rev. 47(3), 361-409 (1983). (Pubitemid 13004241)
52. Biedenbach DJ, Jones RN, Armstrong E S, Aggen JB, Miller GH. Activity of ACHN-490 against complicated urinary tract infection (cUTI) patho gens from the United Stat es and Europe. Presented at: 49th Interscience Conference on Antimicrobi al Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
53. Landman D, Babu E, Shah N et al. Activity of a novel aminoglycoside, ACHN-490, against clinical is olates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother. 65(10), 2123-2127 (2010).
54. Landman D, Kelly P, Backer M et al. An timicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City J. Antimicr ob. Chemother. 66(2), 332-334 (2011).
55. Quale J, Shah N, Babu E et al. Activity of ACHN-490, a Neoglycoside, against E. coli (EC) and K. pneumoni ae (KP) Isolates from New York City (NYC). Presented at: 50th Interscience Conference on Antimicrobi al Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
56. Tenover FC, Tickler I, Armstrong E S, et al. Activity of ACHN-490 against methicillin-resistant staphylococcus aureus (MRSA) from patients in U.S. hospitals. Int. J. Ant imicrob. Agents, 38(4), 352-354 (2011).
57. Endimiani A, Hujer KM, Hujer AM et al. A CHN-490, a neoglycosid e with potent in vitro ac tivity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53(10), 4504-4507 (2009).
58. Galani I, Souli M, Daikos G et al. Activity of ACHN-490 against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli and Enterobacter spp from Athens, Greece. Presented at: 21st Europe an Co ngress of Clinical Mi crobiolog y and Infectious Diseases Milan, Italy, 7-10 May 2011.
59. Heine HS, Miller L, Halasohoris S et al. Activity and efficacy of ACHN-490, a broad-spectrum next-generation aminoglycoside, against Yersinia pe stis and Francisella tularensis. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, BC, Canada 21-24 October 2010.
60. Jones RN, Armstrong E S, Aggen JB, Biedenbach DJ, Miller GH. Antimicrobial Activity of ACHN-490, a neoglycoside, tested against a contemporary collection of clinical is olates in cluding problematic antimicrobial-resistant phenotypes. Presented at: 49th Interscience Conference on Antimicrobi al Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
61. Kotlovsky T, Navon-Venezia S, Keren L, Carmeli Y. ACHN-490 as a potential addition to the antimicrobial armamentarium in ICUs with high levels of resistant organisms. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, 7-10 May 2011.
62. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66(1), 48-53 (2011).
63. Pankuch GA, Lin G, Kubo A, Armstrong E S, Appelbaum P C, Kosowska-Shick K. Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55(5), 2463-2465 (2011).
64. Pulse M, Weiss WJ, Reyes N et al. Efficacy of ACHN-490 in a murine urinary tract infection model with Escherichia coli. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, BC, Canada, 21-24 October 2010.
65. Reyes N, Aggen JB, Kostrub CF. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob. Agents Chemother. 55(4), 1728-1733 (2011).
66. Endimiani A, Hujer AM, Perez F et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J. Antimicrob. Chemother. 63(3), 427-437 (2009).
67. Hirakata Y, Matsuda J, Miyazaki Y et al. Regional variation in the prevalence of extended-spectrum |3-lactamase-producingc linicalisolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn. Microbiol. Infect. Dis. 52(4), 323-329 (2005). (Pubitemid 41297571)
68. Bauer LA. The ami noglycoside antibiotics. In: Applied Clinical Pharmacokinetics. McGraw-Hill Medical, NY, USA (2008).
69. Bruss J. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered int ravenously in human subjects. Presented at: 49th Int erscience Conference on Ant imicrobial Agents and Che motherapy. San Francisco, CA, USA, 12-15 September 2009.
70. Cass R, McKinnell J, Xie B, Karr D, Schmidt D. Pharmacokinetics of the novel neo glycoside ACHN-490 in mouse, rat, and dog. Presented at: 49th Interscience Conference on Ant imicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
71. Cass RT, Books CD, Havrilla N, Tack K, Borin MT, Young D, Bruss J. Pharmacokinetics (PK) and safety of single and multiple doses of ACHN-490 injection administered int ravenously in healthy human subjects. Antimicrob. Agents Chemother. 55(12), 5874-5880 (2011).
72. Kostrub C, Dolan D, Altschuler R et al. Ototoxic potential of ACHN-490 compared to gentamicin and amikacin in the guinea pig. Presented at: 21st European Congress of Cli nical Mic robiology and Infectious Diseases. Milan, Italy, 7-10 May 2011.
73. VanWart S. Population pharmacokinetics of ACHN-490 injection in healthy subjects. Presented at: 48th Annual Meeting of the Inf ectious Diseases Society of America. Vancouver, BC, Canada, 21-24 October 2010.
74. Zurenko G, Stapert D, Knechtel M et al. The bactericidal activity of the neo glycoside ACHN-490 against aminoglycoside-resistant bacteria. Presented at: 49th Interscience Conference on Ant imicrobial Agents and Che motherapy. San Francisco, CA, USA, 12-15 September 2009.
75. Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive res istance. Pharmacotherapy 17(3), 549-555 (1997).
76. Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob. Agents Chemother. 54(5), 2258-2261 (2010).
77. Lode H, Grunert K, Koeppe P, Langmaack H. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J. Infect. Dis. 134(Suppl.), S316-S322 (1976).
78. Lode H, Kemmerich B, Koeppe P. Comparative cli nical pharmacology of gentamicin, sisomicin, and tobramycin. Ant imicrob. Agents Chemother. 8(4), 396-401 (1975).